CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Preço · Ago 19, 2026
Fundamentais a partir de Ago 3, 2026
Intervalo 52 Semanas
$29–$85
100% of range
Classificação do Analista
HOLD
21 analysts
Preço-Alvo
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Margem de Lucro Líquido
-6046.2%
Sobre Crinetics Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Ler mais
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
CRNX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$84.77
Capitalização de Mercado
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Receita (TTM)
$8M
Rendimento div.
—
ROE
-43.0%
Dívida/Capital
—
Intervalo 52 Semanas
$29 – $85
CRNX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Fluxo de caixa livre
$-384M
2018-12-31
→
2025-12-31
Margens
-6046.2%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
CRNX
Mediana de Pares
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF (Preço / FCF)
-21.1
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
CRNX
Mediana de Pares
Operating Margin (Margem Operacional)
-6714.8%
—
Net Profit Margin (Margem de Lucro Líquido)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
CRNX
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
12.3
2.7
Quick Ratio (Índice de Liquidez Seca)
12.1
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
CRNX
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
640.7%
—
Revenue CAGR 3Y (CAGR Receita 3A)
17.6%
—
Revenue CAGR 5Y (CAGR Receita 5A)
155.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
CRNX
Mediana de Pares
CRNX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
MANTER
21 analistas
- Compra forte 3 14,3%
- Compra 4 19,0%
- Manter 14 66,7%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
10 analistas · 2026-08-13
Mediana
$85.00
Média
$85.50
← Abaixo de todos os alvos
$84.77
Mín
$85.00
Máx
$90.00
Alvo mediano
$85.00
+0,3%
Alvo médio
$85.50
+0,9%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.01%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 de Março de 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 de Dezembro de 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 de Setembro de 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 de Junho de 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 de Março de 2025 | $-1.04 | $-0.96 | -0.08% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Balanço Patrimonial 24
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Fluxo de Caixa 13
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Demonstração de Resultados 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Balanço Patrimonial 23
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Fluxo de Caixa 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Lucratividade 6
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $8M | $1M | $4M | $5M | $1M |
| Margem Operacional % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Lucro líquido | $-465M | $-298M | $-215M | $-164M | $-108M |
| EPS Diluído | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Índice de Liquidez Seca | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-384M | $-230M | $-171M | $-117M | $-89M |
Últimas notícias Notícias recentes mencionando esta empresa
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 286 declarantes · $3.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 63 (+17 vs trimestre anterior) | 30 (-14 vs trimestre anterior) | 95 (-17 vs trimestre anterior) | 63 (+3 vs trimestre anterior) | +21.6M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| FMR LLC | $486.250.673 | 12.994.406 | 15,13% | Ações |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336.372.047 | 8.989.098 | 10,46% | Ações |
| Driehaus Capital Management LLC | $241.866.078 | 6.463.551 | 7,52% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $237.002.526 | 6.333.579 | 7,37% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180.836.416 | 4.832.614 | 5,63% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $177.567.704 | 4.745.262 | 5,52% | Ações |
| STATE STREET CORP | $100.635.477 | 2.689.350 | 3,13% | Ações |
| Bellevue Group AG | $98.040.400 | 2.620.000 | 3,05% | Ações |
| BAKER BROS. ADVISORS LP | $87.991.820 | 2.351.465 | 2,74% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $87.542.675 | 2.338.905 | 2,72% | Ações |
| Polar Capital Holdings Plc | $85.108.460 | 2.274.411 | 2,65% | Ações |
| Pictet Asset Management Holding SA | $77.572.984 | 2.075.375 | 2,41% | Ações |
| Siren, L.L.C. | $53.165.887 | 1.420.788 | 1,65% | Ações |
| First Light Asset Management, LLC | $50.923.606 | 1.360.866 | 1,58% | Ações |
| NOVO HOLDINGS A/S | $49.394.400 | 1.320.000 | 1,54% | Ações |
| AMERICAN CENTURY COMPANIES INC | $47.245.129 | 1.262.562 | 1,47% | Ações |
| ADAR1 Capital Management, LLC | $45.730.234 | 1.222.080 | 1,42% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $44.555.208 | 1.190.679 | 1,39% | Ações |
| MONTANOVA CAPITAL, LLC | $44.390.560 | 1.186.279 | 1,38% | Ações |
| ORBIMED ADVISORS LLC | $37.382.580 | 999.000 | 1,16% | Ações |
| Hood River Capital Management LLC | $36.259.830 | 968.996 | 1,13% | Ações |
| GOLDMAN SACHS GROUP INC | $34.657.132 | 926.166 | 1,08% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32.841.401 | 877.643 | 1,02% | Ações |
| Aberdeen Group plc | $30.699.181 | 820.395 | 0,95% | Ações |
| Candriam S.C.A. | $30.618.690 | 819.032 | 0,95% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $28.230.995 | 754.436 | 0,88% | Ações |
| Fisher Asset Management, LLC | $27.748.912 | 741.553 | 0,86% | Ações |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17.709.036 | 479.400 | 0,55% | Ações |
| AMERIPRISE FINANCIAL INC | $17.451.149 | 466.356 | 0,54% | Ações |
| Impax Asset Management Group plc | $16.277.700 | 435.000 | 0,51% | Ações |
| Prosight Management, LP | $14.020.002 | 374.666 | 0,44% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13.991.714 | 373.910 | 0,44% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.685.018 | 365.714 | 0,43% | Ações |
| BRAUN STACEY ASSOCIATES INC | $13.027.511 | 348.143 | 0,41% | Ações |
| Fiera Capital Corp | $12.395.263 | 331.247 | 0,39% | Ações |
| BANK OF AMERICA CORP /DE/ | $11.271.877 | 301.226 | 0,35% | Ações |
| Defilade Capital Management, L.P. | $8.959.845 | 239.440 | 0,28% | Ações |
| SEB Asset Management AB | $8.003.786 | 213.891 | 0,25% | Ações |
| Foresite Capital Management VI LLC | $7.933.414 | 212.010 | 0,25% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $7.346.220 | 196.318 | 0,23% | Ações |
| TD Asset Management Inc | $7.152.534 | 191.142 | 0,22% | Ações |
| Swiss National Bank | $6.877.796 | 183.800 | 0,21% | Ações |
| SEGALL BRYANT & HAMILL, LLC | $6.855.307 | 183.199 | 0,21% | Ações |
| BlackRock, Inc. | $6.781.290 | 181.221 | 0,21% | Ações |
| JENNISON ASSOCIATES LLC | $6.056.839 | 161.861 | 0,19% | Ações |
| New Leaf Venture Partners, L.L.C. | $5.872.650 | 141.000 | 0,18% | Ações |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.865.136 | 156.738 | 0,18% | Ações |
| Foresite Capital Management IV, LLC | $5.613.000 | 150.000 | 0,17% | Ações |
| Bank of New York Mellon Corp | $5.581.754 | 149.165 | 0,17% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $5.508.898 | 147.218 | 0,17% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $5.471.384 | 146.216 | 0,17% | Ações |
| Moody Aldrich Partners LLC | $5.466.201 | 146.077 | 0,17% | Ações |
| Ishara Investments LP | $5.369.770 | 143.500 | 0,17% | Ações |
| CITADEL ADVISORS LLC | $5.176.271 | 138.329 | 0,16% | Ações |
| RHUMBLINE ADVISERS | $4.861.141 | 129.908 | 0,15% | Ações |
| ALLIANCEBERNSTEIN L.P. | $4.782.618 | 131.680 | 0,15% | Ações |
| GordonMD Global Investments LP | $4.751.779 | 126.985 | 0,15% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4.712.974 | 125.948 | 0,15% | Ações |
| JANUS HENDERSON GROUP PLC | $4.700.428 | 129.392 | 0,15% | Ações |
| Cormorant Asset Management, LP | $4.677.500 | 125.000 | 0,15% | Ações |
| SECTOR GAMMA AS | $4.289.380 | 114.628 | 0,13% | Ações |
| XTX Topco Ltd | $4.164.547 | 111.292 | 0,13% | Ações |
| ALPS ADVISORS INC | $3.981.825 | 106.409 | 0,12% | Ações |
| FEDERATED HERMES, INC. | $3.957.390 | 105.756 | 0,12% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.834.048 | 105.563 | 0,12% | Ações |
| Nuveen Asset Management, LLC | $3.760.151 | 73.541 | 0,12% | Ações |
| Burkehill Global Management, LP | $3.742.000 | 100.000 | 0,12% | Ações |
| Nuveen, LLC | $3.619.262 | 96.720 | 0,11% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $3.484.251 | 93.112 | 0,11% | Ações |
| MORGAN STANLEY | $3.320.829 | 88.744 | 0,10% | Ações |
| TWO SIGMA INVESTMENTS, LP | $3.266.729 | 87.299 | 0,10% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.254.754 | 86.979 | 0,10% | Ações |
| AWM Investment Company, Inc. | $3.180.700 | 85.000 | 0,10% | Ações |
| Odyssean, LLC | $3.160.344 | 84.456 | 0,10% | Ações |
| Affinity Asset Advisors, LLC | $2.806.500 | 75.000 | 0,09% | Ações |
| ALGERT GLOBAL LLC | $2.714.147 | 72.532 | 0,08% | Ações |
| ExodusPoint Capital Management, LP | $2.652.404 | 70.882 | 0,08% | Ações |
| Ensign Peak Advisors, Inc | $2.507.290 | 67.004 | 0,08% | Ações |
| BARCLAYS PLC | $2.466.127 | 65.904 | 0,08% | Ações |
| FIRST TRUST ADVISORS LP | $2.370.631 | 63.352 | 0,07% | Ações |
| Man Group plc | $2.284.229 | 61.043 | 0,07% | Ações |
| MetLife Investment Management, LLC | $2.258.709 | 60.361 | 0,07% | Ações |
| CITIGROUP INC | $2.255.229 | 60.268 | 0,07% | Ações |
| Longaeva Partners L.P. | $2.184.879 | 58.388 | 0,07% | Ações |
| Swedbank AB | $2.155.392 | 57.600 | 0,07% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.068.016 | 55.265 | 0,06% | Ações |
| Jump Financial, LLC | $1.923.388 | 51.400 | 0,06% | Ações |
| Lighthouse Investment Partners, LLC | $1.871.000 | 50.000 | 0,06% | Ações |
| Vestmark Advisory Solutions, Inc. | $1.823.252 | 48.724 | 0,06% | Ações |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.787.254 | 47.762 | 0,06% | Ações |
| VANGUARD GROUP INC | $1.774.626 | 38.123 | 0,06% | Ações |
| Point72 Asset Management, L.P. | $1.735.577 | 46.381 | 0,05% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $1.696.398 | 45.334 | 0,05% | Ações |
| RAYMOND JAMES FINANCIAL INC | $1.606.254 | 42.925 | 0,05% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.549.188 | 41.400 | 0,05% | Opção de compra |
| Invesco Ltd. | $1.545.446 | 41.300 | 0,05% | Ações |
| Vanguard Global Advisers, LLC | $1.485.986 | 39.711 | 0,05% | Ações |
| HighMark Wealth Management LLC | $1.444.224 | 38.595 | 0,04% | Ações |
| OAK RIDGE INVESTMENTS LLC | $1.405.046 | 37.548 | 0,04% | Ações |
| Orion Porfolio Solutions, LLC | $1.404.234 | 37.526 | 0,04% | Ações |
Executivos da empresa 20 insiders · 9 diretores · 10 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 de Março de 2025 A | 52.000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 de Setembro de 2024 M | 111.092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 de Março de 2025 S | 87.491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 de Junho de 2025 M | 99.713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 de Março de 2025 S | 72.233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 de Janeiro de 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5 de Julho de 2024 M | 29.259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 de Outubro de 2023 M | 43.210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 de Fevereiro de 2022 A | 176.995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Conselheiro | 2 de Julho de 2026 S | 19.225 | 0 | 1 | $-120.000 |
| Caren Deardorf | Conselheiro | 18 de Junho de 2026 A | 22.225 | 0 | 0 | $0 |
| Weston Nichols | Conselheiro | 18 de Junho de 2026 A | 22.225 | 0 | 0 | $0 |
| Stephanie Okey | Conselheiro | 18 de Junho de 2026 A | 12.325 | 0 | 2 | $-246.143 |
| Matthew K Fust | Conselheiro | 18 de Junho de 2026 A | 28.761 | 0 | 0 | $0 |
| Camille L Bedrosian | Conselheiro | 18 de Junho de 2026 A | 22.225 | 0 | 0 | $0 |
| Wendell Wierenga | Conselheiro | 18 de Junho de 2026 A | 122.071 | 0 | 0 | $0 |
| Wendall Wierenga | Conselheiro | 11 de Junho de 2025 A | 116.146 | 0 | 0 | $0 |
| Stephen W Kaldor | Conselheiro | 19 de Junho de 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Conselheiro | 21 de Junho de 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7 de Agosto de 2026 M | 424.706 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 declarações | 1 de Março de 2024 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 55 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107.892 NS | 31 de Maio de 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376.636 SH | 8 de Agosto de 2026 | Diário |
| FMED · Fidelity Covington Trust | 1,65% | 19.000 NS | 31 de Maio de 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4.666 NS | 30 de Abril de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18.743 NS | 30 de Abril de 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11.043 NS | 31 de Maio de 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718.323 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5.737 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,54% | 940.202 SH | 8 de Agosto de 2026 | Diário |
| NUSC · Nushares ETF Trust | 0,28% | 93.045 NS | 30 de Abril de 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32.694 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,27% | 2.625.192 SH | 8 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110.770 SH | 8 de Agosto de 2026 | Diário |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38.553 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3.872 NS | 31 de Maio de 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55.438 SH | 8 de Agosto de 2026 | Diário |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3.142 NS | 30 de Abril de 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51.135 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18.879 NS | 30 de Abril de 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4.625 SH | 8 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596.648 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,12% | 42.391 NS | 30 de Abril de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1.399.667 SH | 8 de Agosto de 2026 | Diário |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31.759 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4.601 NS | 31 de Maio de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2.909 SH | 8 de Agosto de 2026 | Diário |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492.431 NS | 31 de Maio de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24.991 NS | 30 de Abril de 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5.742 SH | 8 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41.183 NS | 30 de Abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196.549 NS | 30 de Abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3.599 NS | 31 de Maio de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2.419.186 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,05% | 275.155 SH | 8 de Agosto de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5.196 NS | 30 de Abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.210.574 SH | 8 de Agosto de 2026 | Diário |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 de Maio de 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3.643 NS | 31 de Maio de 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.689 NS | 31 de Maio de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3.773 NS | 31 de Maio de 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 de Maio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146.419 SH | 8 de Agosto de 2026 | Diário |
| IWV · iShares Trust | 0,01% | 27.043 SH | 8 de Agosto de 2026 | Diário |
| DFAC · Dimensional ETF Trust | 0,01% | 125.853 NS | 30 de Abril de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3.342.704 SH | 8 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.345 SH | 8 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22.843 SH | 8 de Agosto de 2026 | Diário |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28.694 NS | 31 de Maio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.863 NS | 30 de Abril de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.388 NS | 30 de Abril de 2026 | N-PORT |